Results 141 to 150 of about 51,607 (296)
What is your diagnosis? Abnormal cluster on the WDF and WNR scattergrams from Sysmex XN‐V in a dog
Veterinary Clinical Pathology, EarlyView.
Theo Chenal+3 more
wiley +1 more source
ABSTRACT Background Coexisting primary hematologic malignancies in untreated multiple myeloma (MM) are rare. Case A 69‐year‐old man with smoldering multiple myeloma (sMM) presented with lymphadenopathies and an intracranial mass. He was diagnosed with diffuse large B‐cell lymphoma (DLBCL), classic Hodgkin lymphoma (cHL), and sMM. The patient received R‐
Giusy Ceparano+5 more
wiley +1 more source
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia [PDF]
Martin S. Tallman+6 more
openalex +1 more source
The study revealed distinct drug sensitivity patterns across acute myeloid leukaemia (AML) French–American–British (FAB) subtypes and mutations. The findings underscore the importance of integrating FAB classifications and mutation profiles in treatment decisions.
Mobina Shrestha+4 more
wiley +1 more source
No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission [PDF]
Jean‐Yves Cahn+12 more
openalex +1 more source
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine [PDF]
David Sternberg+6 more
openalex +1 more source
Central nervous system relapse of primary cutaneous anaplastic large cell lymphoma: A case report
Abstract Primary cutaneous anaplastic large cell lymphoma (PC‐ALCL) has a high relapse rate. However, it typically remains confined to the skin and has a favorable long‐term prognosis. We describe a case of PC‐ALCL that experienced a relapse in the central nervous system (CNS).
Satoshi Mitsuyuki+7 more
wiley +1 more source
Background Despite recent advances, optimal therapeutic approaches applicable to subpopulations with primary central nervous system (CNS) lymphoma outside of clinical trials remain to be determined.
Maciej Tatarczuch+26 more
doaj +1 more source
Acute cerebellar syndrome following intermediate‐dose cytarabine [PDF]
Moshe Yeshurun, K Dupuch
openalex +1 more source